Video

Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP

Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.

Related Videos
Related Content
HOPA 2025: Matthew Lei, PharmD, BCOP, Shares Critical Themes and Hot Topic Sessions
April 9th 2025

HOPA 2025: Matthew Lei, PharmD, BCOP, Shares Critical Themes and Hot Topic Sessions

Matthew M. Lei, PharmD, BCOP Alana Hippensteele, Lead Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Depiction of anemia, reduced red blood cells in bloodstream | Image Credit: © Prime Stox - stock.adobe.com
April 4th 2025

MANIFEST-2 Study: Pelabresib Plus Ruxolitinib Is Superior to JAK Inhibitors Alone

Alexandra Gerlach, Associate Editor
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Chemical structure of MDM2 protein binding p53 | Image Credit: © Juan Gärtner - stock.adobe.com
April 3rd 2025

Siremadlin Demonstrates Efficacy, Safety in Treatment of Patients With TP53 Wild-Type Chronic Lymphocytic Leukemia

Alexandra Gerlach, Associate Editor
Visualization of a CAR T-cell | Image Credit: © DruZhi Art - stock.adobe.com
April 3rd 2025

Nivolumab May Restore T-Cell Fitness Following CAR T-Cell Therapy in Patients With Multiple Myeloma

Alexandra Gerlach, Associate Editor